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Summary
  Semicarbazide-sensitive amine oxidase (SSAO) is a multi-functional enzyme widely present in na-
ture. It converts primary amines into their corresponding aldehydes, while generating H2O2 and 
NH3. In mammals, SSAO circulates in plasma, while a membrane-bound form (often referred to 
as vascular adhesion protein-1, VAP-1) is found in many tissues and organs, especially in adipocytes 
and vascular endothelial and smooth muscle cells. In recent years, evidence has been accumulat-
ing that SSAO has a role in protein cross-linking, formation of advanced glycation end-products, 
atherogenesis, glucose regulation and leukocyte extravasation at infl ammation sites. Plasma SSAO 
is quite stable in healthy adults, but is elevated in diabetes mellitus (both type 1 and type 2), conges-
tive heart failure and liver cirrhosis. The origin of circulating SSAO remains unclear, but recent ev-
idence from clinical studies and from (transgenic) animal studies suggests that adipocytes and vas-
cular endothelial cells may be the most important source. Studies with cell cultures show evidence 
that the membrane-bound SSAO can be split off from the cells, thus giving rise to the (truncated) 
circulating form of SSAO. In some pathological conditions the diseased organ may be the main 
source of the elevated plasma SSAO. Little is known as yet about the regulation of plasma SSAO. 
Thyroid hormone appears to play a (modest) role in this respect. Further evidence from clinical, 
animal and cell-culture studies, helped by the new availability of selective SSAO inhibitors, is need-
ed to shed more light on the question of the regulation of SSAO.
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BACKGROUND
Semicarbazide-sensitive amine oxidase (SSAO; E.C.1.4.3.6) 
is a common name for a group of copper-containing amine 
oxidases widely present in nature in microorganisms, plants, 
and animals, including man [1,2]. Biochemically, SSAO con-
verts primary amines into the corresponding aldehydes, gen-
erating at the same time hydrogen peroxide and ammonia. 
In man, methylamine and aminoacetone have been report-
ed to be natural substrates, leading to formation of the tox-
ic products formaldehyde and methylglyoxal, while exoge-
nous compounds such as benzylamine and allylamine are 
ready substrates for the enzyme. Depending on the species 
concerned, other amines, such as serotonin, dopamine, tryp-
tamine etc, can also be converted. SSAO has a different in-
hibitor pattern than the monoamine oxidases MAO-A and -
B, which catalyze the same reaction, although not always with 
the same substrates. Methylamine and aminoacetone, for ex-
ample, are not substrates for MAO-A or -B. The name SSAO 
was coined because semicarbazide is a good inhibitor of the 
enzyme, through reaction with the functional carbonyl group 
of SSAO, a topaquinone entity formed posttranslationally by 
modifi cation of a tyrosine unit in the amino acid chain [3].
SSAO is encountered both in a circulating form in plasma, 
and as a membrane-bound form with a short cytoplasmic 
tail, a single transmembrane part, and a large, highly glyc-
osylated, extracellular domain containing the active center. 
Membrane-bound SSAO has been found to be identical to 
the vascular adhesion protein known as VAP-1 [4].
The functional role of SSAO remains rather unclear, and is 
probably manifold. It may protect against the negative effects 
of endogenous or exogenous amines by enzymatic transfor-
mation, which, however, may sometimes lead to even more 
toxic products than the original amines. This is the case, for 
example, with allylamine, which in itself is not very toxic, 
while reaction with SSAO forms the highly potent cardiotox-
ic substance acrolein [5]. The reactive aldehydes formed by 
SSAO from methylamine and aminoacetone are implicated 
in the cross-linking of proteins, which is sometimes useful, 
but may also lead to advanced glycation end products [6–
10]. Experimental evidence also seems to indicate a role for 
SSAO in apoptosis and atherogenesis [11,12]. The (local) 
production of hydrogen peroxide, a signaling molecule, by 
reaction of SSAO with a substrate, may be important in spe-
cifi c circumstances. This is the case, for example, in the role 
SSAO plays in promoting glucose transport into the cells by 
recruitment of the GLUT4 transporter to the cell membranes, 
a process that can be blocked by the hydrogen peroxide scav-
enger catalase [13]. The VAP-1 side of SSAO is responsible 
for leukocyte traffi cking at infl ammation sites [4].
(Patho)physiology
In humans, SSAO can be found in most organs and tissues, 
especially in vascular endothelial and smooth muscle cells, 
adipocytes and the umbilical cord. It also circulates in plas-
ma, where its activity normally appears to be well-regulated 
and stable. In healthy adults, the SSAO activity remains with-
in the range of 150–550 mU/l until about 60 years of age, 
when it slowly starts increasing (Figure 1). Interestingly, in 
children from birth to age 16, plasma SSAO activity is sub-
stantially higher (Figure 1).
In some pathological conditions, plasma SSAO activities 
have been found to be signifi cantly elevated [14–19]. This 
is the case in several pathologies (Figure 2):
1.  diabetes mellitus, both type 1 and type 2 (DM1 and 
DM2);
2. congestive heart failure (CHF);
3. liver cirrhosis.
Figure 1.  Normal plasma SSAO activities (mean ±SD) in diff erent age 
ranges. N – number of subjects.
Figure 2.  Plasma SSAO activities (mean ±SD) in controls and patients 
with various diseases. Cont.– controls; DM1 – diabetes 
mellitus type 1; DM2 – diabetes mellitus type 2; CHF 
(+DM) – congestive heartfailure (+diabetes mellitus); 
(HN)LC – (hyponatriemic) liver cirrhosis.
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In DM, the elevation is greater, with increasing occurrence 
of complications; the elevation is already present in children 
at fi rst diagnosis of DM1 [15]. In CHF, also, elevations in 
plasma SSAO refl ect the severity of the disease, as shown by 
the association of plasma SSAO activity with survival [20]. 
In liver cirrhosis, the elevated activities of SSAO are prob-
ably a refl ection of the increased VAP-1 expression at the 
site of infl ammation [19]. This may be specifi c for liver in-
fl ammation, since other infl ammatory diseases, such as col-
itis ulcerosa and Sjøgren’s disease, are not accompanied by 
elevations in plasma SSAO [2].
Mainly experimental data seem to indicate possible roles for 
and changes in SSAO activity in various pathophysiological 
conditions, such as stroke and Alzheimer’s disease, but no 
fi rm data from human studies are available as yet.
Decreases in plasma SSAO are less commonly found, and 
should be looked at with caution. Although this is not wide-
ly known, some commonly used drugs are good inhibitors of 
SSAO, e.g. benserazide and carbidopa (Parkinson’s disease), 
isoniazide (tuberculosis), hydralazine (hypertension), amino-
guanidine (DM), imipramine (depression)[2]. Very low activi-
ties have been reported in children born with hernia diaphrag-
matica, which normalizes after successful surgical correction 
[2]. In 152 patients with chronic renal failure on hemodial-
ysis, plasma SSAO activity was found to be signifi cantly low-
er than in 107 healthy controls (300±157 vs. 370±112 mU/
l, p<0.0001, Figure 3). The actual decrease is probably even 
greater, since quite a few of these renal failure patients will also 
have DM or CHF, which would tend to increase plasma SSAO 
activities. This fi nding contrasts with the report of increased 
plasma SSAO (=soluble VAP-1) in patients with end-stage re-
nal failure, which normalizes after transplantation [21].
Clues for sources
There is a great lack in knowledge about the origin of the 
circulating SSAO and its relation to the membrane-bound 
form, which severely hampers investigations into the regu-
lation of plasma SSAO. It has been suggested that sheddases 
cut the membrane-bound SSAO at the extracellular stalk re-
gion, and that the circulating SSAO is thus a truncated ver-
sion, a process known to occur for many membrane-bound 
proteins [19,22,23]. The possibility of different genes or dif-
ferent combinations of encoding regions, however, cannot 
be excluded. There is some experimental evidence that in-
deed metallo-proteases are able to cut off the extracellu-
lar part of membrane-bound SSAO in cultured adipocytes, 
since the metalloprotease inhibitor batimastat prevented re-
lease of SSAO from adipocytes [24]. We ourselves have also 
found that both N-ethylmaleimide, a general shedding-in-
ducing agent, as well as phorbolesters which induce shed-
ding via PKC, are able to stimulate release of SSAO from 
adipocytes. Recent experiments with transgenic and knock-
out mice strongly suggest that the membrane-bound VAP-
1 was the only source for plasma SSAO activity in these an-
imals [25]. Whether the same goes for other tissues and 
cells and other species is not yet known. Probably circulat-
ing SSAO is thus indeed the truncated form of membrane-
bound SSAO, but defi nite proof is still lacking.
In a few instances it has been shown that elevated plas-
ma SSAO activities can be brought down to normal levels 
again. This was reported to be the case in two patients with 
severe liver cirrhosis, whose highly elevated plasma SSAO 
became completely normalized after liver transplantation 
[2]. This would suggest that at least in these cases the (dis-
eased) liver was the source of the elevated SSAO; howev-
er, an alternative explanation, that an unknown substance 
from the diseased liver induces production of SSAO else-
where or regulates its clearance, cannot be completely ruled 
out. A similar case has been reported, a pregnant woman 
with diabetes insipidus and strongly elevated plasma SSAO 
throughout pregnancy [2]. After birth of the baby, the plas-
ma SSAO activity of the mother rapidly normalized with-
in two days, suggesting that in this case the umbilical cord 
Figure 3.  Plasma SSAO activities (mean ±SD) in controls vs. patients 
with chronic renal failure (CRF). N – number of subjects. 
*** p<0.0001 CRF vs. controls.
Disease Medication
SSAO-start SSAO-end
(mean ±SD, mU/l)
Heart failure Carvedilol  521±193  544±231
Atherosclerosis Statins  466±163  459±161
Hep. C virus Glycyrrhizine  489±175  473±125
Colitis ulcerosa Nicorette  381±104  395±105
Hypertension Enalapril  432±97  439±105
+ Candesartan  453±100
Diabetes type 1 Enalapril  736±148
+ Candesartan  743±148
Diabetes type 2 Pioglitazone  588±116  583±121
ACE-inhibitor  697±193
+ARB  703±186
Table 1. Eff ects of medication on plasma SSAO activities.
ACE – angiotensin-converting enzyme; ARB – angiotensin receptor 
blocker.
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and placenta were the origin of the increased SSAO (the 
baby had normal plasma SSAO for its age). Recent studies 
in mice suggest that plasma SSAO originates from both en-
dothelial cells and adipocytes [25].
In view of the possible relation between vascular sclerotic dis-
eases and plasma SSAO, we are presently investigating whether 
surgical correction of atherosclerotic lesions infl uences plas-
ma SSAO activities. Preliminary data seem to indicate that, 
indeed, surgery for coronary artery disease can lead to a low-
ering of elevated plasma SSAO activities, suggesting that pos-
sibly the heart can also be a source of plasma SSAO.
Clues for regulation
An interesting question is whether drugs known to be ben-
efi cial in various syndromes, involving elevated or normal 
plasma SSAO, have effects on plasma SSAO. Some results 
from studies along these lines are given in Table 1. So far, 
no effects of any drug on plasma SSAO activity are proven. 
Once plasma SSAO is elevated, the drugs investigated do 
not seem to be able to reverse the increase in production, 
despite favorable results on progression of the disease.
Studies on associations of plasma SSAO with other systems in-
volved in a particular disease may give clues as to common fac-
tors involved in their regulation. In preeclamptic patients no as-
sociation with SSAO could be found in the known endothelial 
dysfunction markers von Willebrand factor and ED1 fi bronec-
tin [26]. In patients with DM1, plasma SSAO has been reported 
to correlate inversely with circulating insulin concentrations, 
suggesting that insulin regulates plasma SSAO [23]. We have 
recently found, also in patients with DM1, indications for as-
sociations between plasma SSAO and plasma components of 
the renin-angiotensin system, notably angiotensin-converting 
enzyme activity, which might point to a common regulatory 
factor. This is presently under further investigation.
Thyroid hormone is a well-known transcription factor, which 
is also a component of the culture medium used for matu-
ration of pre-adipocytes into adipocytes. We have therefore 
investigated plasma SSAO in patients with hypothyroidism 
and hyperthyroidism, both when they had the disease and 
after appropriate treatment, when they were again euthy-
roid. The results (Figure 4) indicate that plasma SSAO is 
relatively low in patients with hypothyroidism, and increas-
es when the euthyroid state is reached, while plasma SSAO 
is relatively high in patients with hyperthyroidism, and de-
creases when the euthyroid state is reached. This suggests 
that thyroid hormone does play a (moderate) role in the 
regulation of plasma SSAO.
The involvement of TNF-a in the regulation of SSAO has 
been described [24,27]. However, an important clue for the 
regulation of plasma SSAO, which is the fact that children 
under 16 years of age have much higher activities than sub-
jects above the age of 16, has so far not been pursued.
Final remarks
Although considerable progress has been made in the past sev-
eral years in unraveling the role and function of the enigmat-
ic SSAO/VAP-1 molecule, its regulation, and its origin, much 
remains to be resolved. Clues obtained from clinical studies, 
combined with experimental work in cell cultures, may be 
helpful in this respect, as are animal studies with or without 
new molecular biological techniques. Care should be taken, 
however, in extrapolating results from animal studies to man, 
in view of the huge differences, especially in plasma SSAO ac-
tivities between different species. Now that specifi c SSAO in-
hibitors are becoming available, we can expect rapid progress 
in the near future in our knowledge on the many facets of this 
interesting, so far little known enzyme/protein and its various 
roles in human physiology and pathophysiology.
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Figure 4.  Plasma SSAO activities (mean ±SD) in patients with hypothyroidism and hyperthyroidism before and after treatment. N – number 
of subjects. * p=0.020 ** p=0.011.
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